Trinity Biotech annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Trinity Biotech Free Cash Flow (FCF) History (TRIB)
Trinity Biotech reported −$4.6M in free cash flow for fiscal 2024, an increase of $7.8M from the previous fiscal year, with a free cash flow margin of −7.47%.
View full Trinity Biotech company overviewTrinity Biotech free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$4.6M | $7.8M | — | −7.47% |
| 2023 | 2023-12-31 | −$12.4M | −$10.3M | — | −21.75% |
| 2022 | 2022-12-31 | −$2.0M | −$13.4M | — | −3.23% |
| 2021 | 2021-12-31 | $11.4M | −$9.2M | −44.47% | +14.08% |
| 2020 | 2020-12-31 | $20.6M | $17.3M | +523.73% | +20.18% |
| 2019 | 2019-12-31 | $3.3M | $3.6M | — | +3.65% |
| 2018 | 2018-12-31 | −$299,000 | −$4.7M | — | −0.31% |
| 2017 | 2017-12-31 | $4.4M | −$1.6M | −26.64% | +4.45% |
| 2016 | 2016-12-31 | $6.0M | −$49,000 | −0.81% | +6.04% |
| 2015 | 2015-12-31 | $6.1M | — | — | +6.05% |
Trinity Biotech quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Trinity Biotech free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $3.3M to −$4.6M, a net decrease of $7.9M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Trinity Biotech filings at SEC.gov ↗